Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: John O'Neill who wrote (19446)	4/22/1998 10:23:00 PM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

JO, I think that LGND has the rights to Targretin and any other rexinoid for breast cancer. LLY has the rights to metabolic disease like diabetes (LGND gets a royalty). I'm really not sure what the exact relationship is with the combo treatment. I suspect that it's some kind of fairly even split, but I don't think that it's spelled out other LLY has rights to develop a drug which I would I would assume is a rexinoid (like LGD1268 and LGD1324), but not Targretin.